A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia–reperfusion injury and inflammation after on-pump coronary artery bypass gr...

Por Opfermann, P, Derhaschnig, U, Felli, A, Wenisch, J, Santer, D, Zuckermann, A, Dworschak, M, Jilma, B, Steinlechner, B
Publicado no Clin Exp Immunol (2015)